Abstract
Purpose
The renin-angiotensin system plays a crucial role in maintaining vascular homeostasis. Stimulation of angiotensin II type 1 receptors (AT1R) acts proangiogenically by increasing levels of vascular endothelial growth factor (VEGF). Consequently, cell culture experiments and animal studies have shown antiproliferative effects of AT1R blockers (ARB) and angiotensin I converting enzyme inhibitors (ACEI) in several malignancies. Until now, very limited clinical data for this antiangiogenic effect exists for combinations with antineoplastic chemotherapy.
Methods
A total of 287 patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy were retrospectively analysed regarding long-term medication with ACEI and ARB as well as histological type, stage, performance status, gender, age, dose-intensity of chemotherapy and survival.
Results
Patients receiving either ACEI or ARB had a 3.1 months longer median survival than non-recipients (11.7 vs. 8.6 months, HR 0.56, P = 0.03). This survival advantage could not be attributed to other established risk-factors or dose intensity of chemotherapy.
Conclusions
Addition of ACEI or ARB to platinum-based first-line chemotherapy may contribute to prolonged survival in patients with advanced lung cancer.
Similar content being viewed by others
References
Alvarez A, Cerda-Nicolas M, Naim Abu Nabah Y et al (2004) Direct evidence of leukocyte adhesion in arterioles by angiotensin II. Blood 104:402–408. doi:10.1182/blood-2003-08-2974
Anandanadesan R, Gong Q, Chipitsyna G et al (2008) Angiotensin II induces vascular endothelial growth factor in pancreatic cancer cells through an angiotensin II type 1 receptor and ERK1/2 signaling. J Gastrointest Surg 12:57–66. doi:10.1007/s11605-007-0403-9
Arrieta O, Guevara P, Escobar E et al (2005) Blockage of angiotensin II type I receptor decreases the synthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat glioma. Br J Cancer 92:1247–1252. doi:10.1038/sj.bjc.6602483
Attoub S, Gaben AM, Al-Salam S et al (2008) Captopril as a potential inhibitor of lung tumor growth and metastasis. Ann N Y Acad Sci 1138:65–72
Christian JB, Lapane KL, Hume AL et al (2008) Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial. J Natl Cancer Inst 100:1223–1232. doi:10.1093/jnci/djn262
Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. N Engl J Med 358:1160–1174. doi:10.1056/NEJMra0707704
Cohen MH, Gootenberg J, Keegan P et al (2007) FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 12:713–718. doi:10.1634/theoncologist.12-6-713
Delbaldo C, Michiels S, Rolland E et al (2007) Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease. Cochrane Database Syst Rev CD004569
Deshayes F, Nahmias C (2005) Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 16:293–299. doi:10.1016/j.tem.2005.07.009
Egami K, Murohara T, Shimada T et al (2003) Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest 112:67–75
Friis S, Sorensen HT, Mellemkjaer L et al (2001) Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer 92:2462–2470. doi:10.1002/1097-0142(20011101)92:9<2462::AID-CNCR1596>3.0.CO;2-L
Fujita M, Hayashi I, Yamashina S et al (2005) Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth. Carcinogenesis 26:271–279. doi:10.1093/carcin/bgh324
Greco S, Muscella A, Elia MG et al (2003) Angiotensin II activates extracellular signal regulated kinases via protein kinase C and epidermal growth factor receptor in breast cancer cells. J Cell Physiol 196:370–377. doi:10.1002/jcp.10313
Jones PH, Christodoulos K, Dobbs N et al (2004) Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancer. Br J Cancer 91:30–36. doi:10.1038/sj.bjc.6601897
Kjeldsen SE, Julius S (2004) Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Am Heart J 148:747–754. doi:10.1016/j.ahj.2004.04.037
Lever AF, Hole DJ, Gillis CR et al (1998) Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 352:179–184. doi:10.1016/S0140-6736(98)03228-0
Li CI, Malone KE, Weiss NS et al (2003) Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65–79 years. Cancer 98:1504–1513. doi:10.1002/cncr.11663
McMillan DC, Elahi MM, Sattar N et al (2001) Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutr Cancer 41:64–69. doi:10.1207/S15327914NC41-1&2_8
Miyajima A, Kosaka T, Asano T et al (2002) Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res 62:4176–4179
Molina JR, Adjei AA, Jett JR (2006) Advances in chemotherapy of non-small cell lung cancer. Chest 130:1211–1219. doi:10.1378/chest.130.4.1211
Noguchi R, Yoshiji H, Kuriyama S et al (2003) Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis. Clin Cancer Res 9:6038–6045
Prisant LM (2008) Management of hypertension in patients with cardiac disease: use of renin-angiotensin blocking agents. Am J Med 121:S8–S15. doi:10.1016/j.amjmed.2008.05.017
Redondo-Muller MA, Stevanovic-Walker M, Barker S et al (2008) Anti-cancer actions of a recombinant antibody (R6313/G2) against the angiotensin II AT1 receptor. Endocr Relat Cancer 15:277–288. doi:10.1677/ERC-07-0068
Rizkalla B, Forbes JM, Cooper ME et al (2003) Increased renal vascular endothelial growth factor and angiopoietins by angiotensin II infusion is mediated by both AT1 and AT2 receptors. J Am Soc Nephrol 14:3061–3071. doi:10.1097/01.ASN.0000099374.58607.C9
Ruilope LM (2005) Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers? Acta Diabetol 42(Suppl 1):S33–S41. doi:10.1007/s00592-005-0179-x
Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98. doi:10.1056/NEJMoa011954
Suzuki Y, Ruiz-Ortega M, Lorenzo O et al (2003) Inflammation and angiotensin II. Int J Biochem Cell Biol 35:881–900. doi:10.1016/S1357-2725(02)00271-6
Takeda H, Kondo S (2001) Differences between squamous cell carcinoma and keratoacanthoma in angiotensin type-1 receptor expression. Am J Pathol 158:1633–1637
Uemura H, Ishiguro H, Nakaigawa N et al (2003) Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther 2:1139–1147
Uemura H, Ishiguro H, Kubota Y (2006) Angiotensin II receptor blocker: possibility of antitumor agent for prostate cancer. Mini Rev Med Chem 6:835–844. doi:10.2174/138955706777698633
Uemura H, Ishiguro H, Kubota Y (2008) Pharmacology and new perspectives of angiotensin II receptor blocker in prostate cancer treatment. Int J Urol 15:19–26
van der Knaap R, Siemes C, Coebergh JW et al (2008) Renin-angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion/deletion polymorphism, and cancer: the Rotterdam Study. Cancer 112:748–757. doi:10.1002/cncr.23215
Volpert OV, Ward WF, Lingen MW et al (1996) Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 98:671–679. doi:10.1172/JCI118838
Williams CJ, Woods R, Levi J et al (1988) Chemotherapy for non-small cell lung cancer: a randomized trial of cisplatin/vindesine v no chemotherapy. Semin Oncol 15:58–61
Yasumatsu R, Nakashima T, Masuda M et al (2004) Effects of the angiotensin-I converting enzyme inhibitor perindopril on tumor growth and angiogenesis in head and neck squamous cell carcinoma cells. J Cancer Res Clin Oncol 130:567–573. doi:10.1007/s00432-004-0582-7
Zambidis ET, Soon Park T, Yu W et al (2008) Expression of angiotensin-converting enzyme (CD143) identifies and regulates primitive hemangioblasts derived from human pluripotent stem cells. Blood 112:3601–3614. doi:10.1182/blood-2008-03-144766
Acknowledgments
We thank A. Spelsberg from the Aachener Tumorzentrum e.V. for providing additional survival data and Oliver Galm for critically reading the manuscript.
Conflict of interest statement
We declare that we have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wilop, S., von Hobe, S., Crysandt, M. et al. Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J Cancer Res Clin Oncol 135, 1429–1435 (2009). https://doi.org/10.1007/s00432-009-0587-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-009-0587-3